

PIRAMAL HEALTHCARE LIMITED
Piramal Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013.

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2010

(Rs. in Lakhs)

Particulars	3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for the previous year ended	Previous accounting year ended
	31/12/2010 (Unaudited)	31/12/2009 (Unaudited)	31/12/2010 (Unaudited)	31/12/2009 (Unaudited)	31/03/2010 (Audited)
Net Sales / Income from Operations	20,544	69,962	131,051	197,050	265,094
Other Operating Income	436	527	969	1,182	1,527
Net Sales / Income from Operations	20,980	70,489	132,020	198,232	266,621
Income from Investments (Refer Note 5)	15,407	2,707	24,211	10,690	13,248
Net Sales / Income from Operations & Investments	36,387	73,196	156,231	208,922	279,869
Expenditure					
(Increase) / Decrease in stock in trade and work-in-progress	(2,113)	(5,578)	6,285	(9,035)	(2,184)
Consumption of Raw Materials	10,948	14,663	24,969	46,544	61,085
Purchase of Traded Goods	1,245	20,415	26,342	44,928	51,362
Employees Cost	3,494	7,019	20,114	22,431	29,893
R&D Expenses	698	734	2,561	2,645	3,619
Depreciation	1,441	2,339	6,281	6,911	9,222
Foreign Exchange (Gain)/Loss (Net)	(1,170)	15	(510)	233	1,061
Other Expenditure (Net)	10,236	15,577	46,141	46,536	62,416
Total Expenditure	24,779	55,184	132,183	161,193	216,474
Profit from Operations before Interest & Exceptional Items	11,608	18,012	24,048	47,729	63,395
Other Income	2	-	3	-	3
Profit before Interest & Exceptional Items	11,610	18,012	24,051	47,729	63,398
Interest Expenses	1,098	3,366	6,677	12,546	15,636
Profit after Interest but before Exceptional Items	10,512	14,646	17,374	35,183	47,762
Exceptional (Income)/Expenses (Net)	-	-	(1,620,990)	36	36
Profit before Tax	10,512	14,646	1,638,364	35,147	47,726
Tax Expense	1,310	818	365,473	2,486	3,404
Net Profit from Ordinary Activities after Tax	9,202	13,828	1,272,891	32,661	44,322
Extraordinary Items (net of tax expense)	-	-	-	-	-
Net Profit for the Period	9,202	13,828	1,272,891	32,661	44,322
Paid-up Equity Share Capital (Face Value Rs.2/- each)	4,180	4,180	4,180	4,180	4,180
Paid-up Debt Capital					35,000
Reserves (Excluding Revaluation Reserves)					145,883
Debenture Redemption Reserve					6,500
Earnings Per Share (EPS)					
a) Basic and diluted EPS before exceptional and extraordinary items for the period (Rs.)	5.0	6.6	8.3	15.6	21.2
b) Basic and diluted EPS before extraordinary items for the period (Rs.)	4.4	6.6	609.0	15.6	21.2
c) Basic and diluted EPS after extraordinary items for the period (Rs.)	4.4	6.6	609.0	15.6	21.2
Public Shareholding					
- Number of shares	97572236	105780645	97572236	105780645	106087962
- Percentage of shareholding	46.68%	50.61%	46.68%	50.61%	50.76%
Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	-	8420000	-	8420000	8420000
- Percentage of shares (% to total shareholding of promoters and promoter group)	-	8.16%	-	8.16%	8.18%
- Percentage of shares (% to the total share capital of the company)	-	4.03%	-	4.03%	4.03%
b) Non-encumbered					
- Number of Shares	111440908	94812499	111440908	94812499	94505182
- Percentage of shares (% to total shareholding of promoters and promoter group)	100.00%	91.84%	100.00%	91.84%	91.82%
- Percentage of shares (% to the total share capital of the company)	53.32%	45.36%	53.32%	45.36%	45.21%



Notes:

1. The standalone financial results, for the quarter and nine months ended December 31, 2010, have been reviewed by the Audit Committee and approved by the Board at its meeting held on February 11, 2011 and are subjected to limited review by the statutory auditors.
2. The only individually reportable business segment is pharmaceutical business.
3. The Company has, pursuant to the approval of its Board of Directors at their meeting held on October 22, 2010 and the approval of its shareholders by Special Resolution passed on December 6, 2010 decided to buyback upto 41,802,629 equity shares of the face-value of Rs.2/- each at a price of Rs.600/- per share aggregating to Rs.2508.2 crores from the shareholders of the Company through a Tender Offer, in accordance with Section 77A of the Companies Act, 1956 and the Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 as amended. Approval from SEBI is awaited.
4. The Company has on 7th September 2010 sold its Domestic Formulations Business (discontinued operations) to Abbott Healthcare Private Limited on slump sale basis resulting in a profit of Rs. 16,006.62 Crore which is included under exceptional Income shown in the year to date figure for the period ended December 31, 2010. The net profit of the Business in respect of the ordinary activities attributable to the discontinued operations is:


(Rs. In crores)

Particulars	For the Quarter Ended December 31		For the nine months Ended December 31	
	2010	2009 (Unaudited)	2010	2009 (Unaudited)
Profit After Tax	-	168.6	150.7	425.7

5. Income from Investments represents the income earned on the temporary investments made out of proceeds from sale of the Domestic Formulation Business and the holding in Piramal Diagnostic Services Private Limited. These temporary investments have been made due to surplus funds available in the interim and shall be deployed in businesses in due course.
6. Shareholder complaints received during the quarter ended December 31, 2010 :

Complaints as at October 01, 2010	3
Complaints received during the quarter ended December 31, 2010	22
Complaints disposed off during the quarter ended December 31, 2010	25
Complaints pending as on December 31, 2010	Nil
7. The figures for the quarter and nine months ended December 31, 2009 and year ended March 31, 2010 have been regrouped, wherever necessary.
8. The figures for the quarter and nine months ended December 31, 2010 are not comparable to the previous quarter and nine months ended December 31, 2009 on account of the sale of Domestic formulation business referred in note 4 above.

For PIRAMAL HEALTHCARE LIMITED



Ajay G. Piramal
Chairman

February 11 2011, Mumbai.